Abstract
Introduction and Aims: This study evaluates the effect of risedronate (Actonel) on proximal femoral bone loss after total hip arthroplasty (THA). Studies have shown that alendronate (Fosamax) reduces periprosthetic bone loss after primary THA. We hypothesise that patients who take risedronate, post-THA, will have less bone loss than patients not taking risedronate.
Method: All patients in this prospective study undergo uncemented THA and follow the same post-operative protocol. Patients in the study group take five mg of risedronate daily, beginning five to seven days pre-operatively, and continuing for 24 months after surgery. Patients randomised to the control group do not receive risedronate. Dual energy x-ray absorptiometry (DEXA) scans of the operated proximal femur are performed on all patients pre-operatively, three to seven days post-operatively, and then six weeks, six months, one year and two years post-operatively. Longitudinal changes in bone mineral density (BMD) are compared within and between the two groups.
Results: Analysis of data for female subjects showed the percent change in BMD (g/cm2) for the control group at six months was −9.71% and for the study group −4.55%. Longitudinal changes in BMD between groups were examined using repeated measures analysis within each gender and were found to be significantly different between groups of females (p=.05). A similar trend was observed among the male subjects. One and two-year prospective data will be presented at the meeting.
Conclusion: Bone loss after THA can increase the rate of failure of THA and cause revision surgery to be more complex and have compromised outcomes. Short-term data reveal significantly decreased bone loss after uncemented THA among patients taking risedronate.
These abstracts were prepared by Editorial Secretary, George Sikorski. Correspondence should be addressed to Australian Orthopaedic Association, Ground Floor, The William Bland Centre, 229 Macquarie Street, Sydney, NSW 2000, Australia.
At least one of the authors is receiving or has received material benefits or support from a commercial source.
